JUN and neoplasm: Importantly, the authors show that the activation of the HLF/c-Jun axis confers tumour cell resistance to sorafenib, supporting previous work showing that JUN expression associates with sorafenib resistance in vitro and in patients with HCC10 and establishing HLF as an upstream regulator of sorafenib resistance induced by c-Jun.4